OverviewSuggest Edit

Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions.  All of the Company's drug candidates are new molecular entities discovered internally by its dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. Lexicon Pharmaceuticals has advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome.

TypePublic
Founded1995
HQThe Woodlands, TX, US
Websitelexpharma.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Feb 2019)202(+17%)
Revenue (FY, 2019)$322.1 M(+410%)
Share Price (Sept 2021)$4.5(-3%)
Cybersecurity ratingBMore

Key People/Management at Lexicon Pharmaceuticals

Raymond Debbane

Raymond Debbane

Chairman
Jeffrey L. Wade

Jeffrey L. Wade

Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer
James F. Tessmer

James F. Tessmer

Vice President of Finance and Accounting
Alan J. Main

Alan J. Main

Executive Vice President, Innovation and Chemical Sciences
Lonnel Coats

Lonnel Coats

President and Chief Executive Officer and Director
Brian T. Crum

Brian T. Crum

Vice President and General Counsel
Show more

Lexicon Pharmaceuticals Office Locations

Lexicon Pharmaceuticals has offices in The Woodlands, Atlanta, Birmingham, Boston and in 26 other locations
The Woodlands, TX, US (HQ)
8800 Technology Forest Pl
Atlanta, GA, US
Atlanta, GA, USA
Birmingham, AL, US
Birmingham, AL, USA
Boston, MA, US
Boston, MA, USA
Charlotte, NC, US
Charlotte, NC, USA
Chicago, IL, US
Chicago, IL, USA
Show all (31)

Lexicon Pharmaceuticals Financials and Metrics

Lexicon Pharmaceuticals Revenue

Lexicon Pharmaceuticals's revenue was reported to be $322.07 m in FY, 2019
USD

Revenue (Q1, 2021)

27.0k

Gross profit (Q1, 2021)

27.0k

Gross profit margin (Q1, 2021), %

100%

Net income (Q1, 2021)

(21.0m)

EBIT (Q1, 2021)

(20.8m)

Market capitalization (14-Sept-2021)

644.0m

Closing stock price (14-Sept-2021)

4.5

Cash (31-Mar-2021)

97.7m

EV

558.0m
Lexicon Pharmaceuticals's current market capitalization is $644 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.8m1.1m2.2m22.9m130.0m83.3m90.3m63.2m322.1m

Revenue growth, %

929%469%(36%)

Cost of goods sold

1.9m2.5m3.2m

Gross profit

88.4m60.7m318.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021

Revenue

555.0k355.0k300.0k199.0k372.0k360.0k214.0k238.0k277.0k676.0k419.0k1.8m376.0k566.0k12.5m20.1m27.7m18.3m12.1m26.9m25.2m13.8m6.9m9.2m9.7m294.4m8.0m6.6m27.0k

Cost of goods sold

225.0k537.0k599.0k533.0k838.0k551.0k553.0k1.3m577.0k568.0k633.0k

Gross profit

18.1m11.5m26.3m24.7m12.9m6.3m8.7m8.4m293.9m7.4m6.0m27.0k

Gross profit Margin, %

99%96%98%98%94%92%94%86%100%93%90%100%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2017FY, 2018FY, 2019

Cash

186.3m30.4m37.5m137.3m46.6m61.7m80.4m36.1m

Accounts Receivable

350.0k1.4m790.0k1.0m4.8m5.9m56.5m

Prepaid Expenses

3.7m6.3m4.6m4.8m4.4m2.7m

Inventories

1.9m4.7m4.2m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2017FY, 2018FY, 2019

Net Income

(116.2m)(110.2m)(104.1m)(100.3m)(4.7m)(129.0m)(120.5m)130.1m

Depreciation and Amortization

4.9m4.2m2.9m1.9m727.0k3.4m3.7m3.7m

Inventories

(1.9m)(2.7m)437.0k

Accounts Payable

(10.4m)995.0k(18.9m)20.1m
USDQ2, 2011

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.6 x
Show all financial metrics

Lexicon Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase III Trials Products

2

Pre-Clinical Phase Products

1

Products

1
Show all operating metrics

Lexicon Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Lexicon Pharmaceuticals Online and Social Media Presence

Embed Graph

Lexicon Pharmaceuticals News and Updates

Lexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

THE WOODLANDS, Texas, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, Septemb…

Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education?

NEW YORK, Aug. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, LXRX, KALA, OWLT, and EDU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Lexicon Pharmaceuticals, Agile Therapeutics, Summit Wireless, Resonant, or Nokia?

NEW YORK, July 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LXRX, AGRX, WISA, RESN, and NOK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions

THE WOODLANDS, Texas, June 25, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be a symposium highlighting sotagliflozin followed by a live video question and answer period during the American Diabetes Association’s 81st Scientific Sessions being h…

Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia

THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX…
Show more

Lexicon Pharmaceuticals Blogs

Lexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

The Woodlands, Texas, September 15, 2021 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 21, 2021 at 1…

Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials

Rapid benefit of sotagliflozin supported by data from the SOLOIST and SCORED trials presented at ESC Congress 2021 - The Digital Experience, including:  33% absolute risk reduction in the composite cardiovascular endpoint in type 2 diabetes patients with acute decompensated heart failure (HF), wit…

Lexicon Pharmaceuticals to Participate in the 2021 Jefferies Virtual Healthcare Conference

The Woodlands, Texas, May 26, 2021 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET.  A webcast of the event …

Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology’s 70th Annual Scientific Session

The Woodlands, Texas, May 13, 2021 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiology’s 70th Annual Scientific Session (ACC.21) being held May 15, 2021 through May 17, 2021: Sun…

Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update

Conference Call and Webcast at 5:00 pm Eastern Time The Woodlands, Texas, May 6, 2021 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones. “We continue to enroll patients in our two proof-…

Lexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021

The Woodlands, Texas, April 29, 2021 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2021 financial results on Thursday, May 6, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss t…
Show more

Lexicon Pharmaceuticals Frequently Asked Questions

  • When was Lexicon Pharmaceuticals founded?

    Lexicon Pharmaceuticals was founded in 1995.

  • Who are Lexicon Pharmaceuticals key executives?

    Lexicon Pharmaceuticals's key executives are Raymond Debbane, Jeffrey L. Wade and James F. Tessmer.

  • How many employees does Lexicon Pharmaceuticals have?

    Lexicon Pharmaceuticals has 202 employees.

  • What is Lexicon Pharmaceuticals revenue?

    Latest Lexicon Pharmaceuticals annual revenue is $322.1 m.

  • What is Lexicon Pharmaceuticals revenue per employee?

    Latest Lexicon Pharmaceuticals revenue per employee is $1.6 m.

  • Who are Lexicon Pharmaceuticals competitors?

    Competitors of Lexicon Pharmaceuticals include ACADIA Pharmaceuticals, MannKind Corporation and Ajinomoto Althea.

  • Where is Lexicon Pharmaceuticals headquarters?

    Lexicon Pharmaceuticals headquarters is located at 8800 Technology Forest Pl, The Woodlands.

  • Where are Lexicon Pharmaceuticals offices?

    Lexicon Pharmaceuticals has offices in The Woodlands, Atlanta, Birmingham, Boston and in 26 other locations.

  • How many offices does Lexicon Pharmaceuticals have?

    Lexicon Pharmaceuticals has 31 offices.